| Ytd | 5.53% | |
| 1y | 102.30% |
| Open | 4.38 | Prev Close | 4.33 | Low | 4.36 | High | 4.43 | Mkt Cap | 289.77M |
| Vol | 26.42K | Avg Vol | 583.87K | EPS | -0.41 | P/E | N/A | Forward P/E | -0.53 |
| Beta | 0.63 | Short Ratio | 42.37 | Inst. Own | 15.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.67 | 200-d Avg | 3.71 | 1yr Est | 11.00 |
GALT News
Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,
Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and c
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosi
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) wit
Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies f
NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotec
NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which missed the
NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the lead
Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeu
NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinica
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics,
Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the an
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get
Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get
Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirr
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that i
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that i
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights li
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) wit
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the an
HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the an
https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18
HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) from Neutr